Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
Rhea-AI Summary
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced that management will participate in the Jefferies Global Healthcare Conference 2026, held June 2-4, 2026 in New York, NY. Management will be available for 1x1 investor meetings on Wednesday, June 3, 2026 via conference scheduling.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CRNX
On the day this news was published, CRNX declined 0.05%, reflecting a mild negative market reaction. Argus tracked a trough of -14.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $3.91B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CRNX gained 2.26% while peers were mixed: IMVT -4.18%, KYMR +1.45%, PTGX +0.87%, VKTX +5.14%, APLS -0.05%. Moves do not indicate a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | -13.8% | Reported Q1 2026 results with PALSONIFY revenue and strong cash balance. |
| Apr 27 | EU drug approval | Positive | -1.2% | European Commission approved PALSONIFY for acromegaly across EU and EEA. |
| Apr 08 | Earnings date set | Neutral | -0.8% | Announced timing and access details for upcoming Q1 2026 earnings call. |
| Mar 26 | Brazil MAA filing | Positive | -7.3% | Submitted Brazil marketing application for PALSONIFY supported by Phase 3 data. |
| Feb 26 | FY 2025 earnings | Positive | -6.0% | Reported Q4 and 2025 results with initial PALSONIFY revenue and cash raise. |
Recent fundamentally positive and regulatory milestones have often been followed by negative next-day moves, suggesting a pattern of weak price follow-through on good news.
Over the last few months, CRNX has transitioned further into a commercial-stage company. Regulatory wins such as EU approval of PALSONIFY and a Brazil MAA submission, alongside Q4 2025 and Q1 2026 earnings, were followed by next-day declines ranging from -0.83% to -13.82%. This conference participation fits into an active period of launches, global filings, and ongoing communication with investors rather than a discrete value-changing catalyst.
Market Pulse Summary
This announcement highlights CRNX management’s participation in a major healthcare conference and availability for 1x1 investor meetings on June 3, 2026. It comes after a series of important milestones: EU approval of PALSONIFY, first-quarter 2026 revenue of $10.7M, and a cash position of $1.3B. Investors may watch how conference discussions reinforce the commercial launch trajectory, global regulatory strategy, and development plans for the broader endocrine pipeline.
AI-generated analysis. Not financial advice.
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY.
Management will be available for 1x1 meetings with investors on Wednesday, June 3, 2026. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ first commercial product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA and EMA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat somatostatin receptor 2 (SST2) expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs are focused on a variety of endocrine targets such as thyroid stimulating hormone (TSH), parathyroid hormone (PTH), somatostatin receptor 3 (SST3), growth hormone (GH), glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP), as well as GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
